DuPont de Nemours, Inc. DD registered a loss from continuing operations of 17 cents per share in the fourth quarter of 2024, compared with a loss of 72 cents per share in the year-ago quarter. 

Barring one-time items, earnings came in at $1.13 per share in the reported quarter, up from 87 cents a year ago. It topped the Zacks Consensus Estimate of 98 cents.

Find the latest earnings estimates and surprises on Zacks Earnings Calendar.

DuPont logged net sales of $3,092 million, marking a 7% year-over-year increase. It also beat the Zacks Consensus Estimate of $3,066.8 million. The upside was due to an 8% increase in volume that more than offset a 1% decline in price. The rise in volume was driven by sustained strong demand in the electronics market, a return of year-over-year growth in medical packaging and biopharma and further growth in water markets.

DuPont de Nemours, Inc. Price, Consensus and EPS Surprise

DuPont de Nemours, Inc. price-consensus-eps-surprise-chart | DuPont de Nemours, Inc. Quote

DuPont’s Segment Highlights

The company's Electronics & Industrial segment reported net sales of $1,506 million in the quarter, an 11% year-over-year increase. It was higher than the consensus estimate of $1,504.2 million. Organic sales grew 10%, driven by an 11% rise in volume, which was modestly offset by a 1% decrease in price.

The Water & Protection unit recorded net sales of $1,359 million, a 6% rise from the previous year, beating the consensus estimate of $1,348.2 million. The upside was due to an 8% increase in volumes, partly offset by 2% lower prices.

DD’s FY24 Results

Earnings (as reported) from continuing operations for full-year 2024 were $1.77 per share compared with $1.09 per share a year ago. Net sales went up around 3% year over year to $12,386 million.

DD’s Financials

DuPont had cash and cash equivalents of $1,850 million at the end of 2024, down around 23% year over year. Long-term debt was $5,323 million, down 32% year over year.

The company generated operating cash flow from continuing operations of $2.3 billion in 2024.

DuPont’s Outlook

DuPont anticipates full-year 2025 net sales to be in the range of $12,800-$12,900 million. Operating EBITDA for the full year is forecast to be $3,325-$3,375 million while adjusted earnings are projected to be $4.30-$4.40 per share for the year.

For the first quarter of 2025, DD forecasts net sales of around $3,025 million, operating EBITDA of roughly $760 million and adjusted earnings of around 95 cents per share. 

DD Stock’s Price Performance

DuPont’s shares have gained 11.3% in a year against the Zacks Chemicals Diversified industry’s 3.4% decline.

Image Source: Zacks Investment Research

DD’s Zacks Rank & Key Picks

DD currently carries a Zacks Rank #3 (Hold).

Better-ranked stocks in the Basic Materials space are Ingevity Corporation NGVT, ICL Group Ltd ICL and Nutrien Ltd. NTR. While NGVT carries a Zacks Rank #1 (Strong Buy), ICL and NTR have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Ingevity is scheduled to release fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for NGVT’s fourth-quarter earnings is pegged at 12 cents. NGVT surpassed the Zacks Consensus Estimate in three of the trailing four quarters while missing once. It has a trailing four-quarter earnings surprise of 95.4%, on average.  

ICL Group is slated to release fourth-quarter results on Feb. 26. The consensus estimate for ICL’s fourth-quarter earnings is pegged at 6 cents. It surpassed the Zacks Consensus Estimate for earnings in each of the last four quarters at an average of 18.1%.

Nutrien is scheduled to release fourth-quarter results on Feb. 19. The Zacks Consensus Estimate for NTR’s fourth-quarter earnings is pegged at 33 cents. NTR has gained around 4% in the past year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report

ICL Group Ltd. (ICL) : Free Stock Analysis Report

Ingevity Corporation (NGVT) : Free Stock Analysis Report

Nutrien Ltd. (NTR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research